Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery (AddEase)

23 juli 2026 bijgewerkt door: Montreal Heart Institute

Effectiveness of Adductor Canal Block in Postoperative Co-analgesia for Cardiac Surgery With Saphenous Vein Harvesting

Adductor Canal Block: Efficacy in Postoperative Pain Management for Cardiac Surgery

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Montreal Heart Institute
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Planned CABG with unilateral or bilateral great saphenous vein (GSV) harvesting, without concomitant valve surgery
  • Age ≥ 18 years
  • Ability to understand the protocol and provide written informed consent
  • ASA physical status I-IV

Exclusion Criteria:

  • Refusal to participate in the study or inability to provide written informed consent
  • Contraindication to adductor canal block (e.g., local infection, allergy to local anesthetics)
  • Pre-existing chronic pain associated with chronic use of analgesic medications other than acetaminophen
  • Pre-existing peripheral neuropathy affecting the leg
  • Participation in two other interventional studies at the Montreal Heart Institute
  • Endoscopic vein harvesting performed by the surgical team instead of open saphenectomy technique

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Adductor canal bloc with bupivacaine + dexmedetomidine
Adductor canal bloc with 0,25% bupivacaine + 20 ucg of dexmedetomidine
Andere namen:
  • Pain relief arm
Placebo-vergelijker: Control arm
Saline solution
Needle insertion mimicking the ACB procedure with injection of a saline solution

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Leg Pain at Rest
Tijdsspanne: Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The primary outcome will be leg pain at rest, measured using a numeric rating scale (NRS 0-10) at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) will be performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total opioid consumption
Tijdsspanne: The first 48 postoperative hours after procedure
Cumulative amount administered, expressed in morphine milligram equivalents (MME), during the first 48 postoperative hours (conversion factors used: hydromorphone 1 mg = morphine 5 mg; fentanyl 100 µg = morphine 10 mg).
The first 48 postoperative hours after procedure
Postoperative pain unrelated to the saphenous territory
Tijdsspanne: Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.

Incidence and characterization of postoperative pain unrelated to the saphenous territory (e.g., thoracic or musculoskeletal pain), assessed at the same time points as saphenous pain using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale (NRS 0-10) performed at 3 hours, 6 hours, 12 hours, and 24 hours after the block injection.
Persistent Postoperative Pain
Tijdsspanne: At 3 and 6 months postoperatively, assessed using the NRS.

Proportion of patients reporting pain ≥4/10 at the harvest site at 3 and 6 months postoperatively, assessed using the NRS.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively, assessed using the NRS.
Overall persistent postoperative pain
Tijdsspanne: At 3 and 6 months postoperatively.

Proportion of patients reporting pain ≥4/10 (all sites combined) at 3 and 6 months postoperatively.

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

At 3 and 6 months postoperatively.
Presence of hypoesthesia
Tijdsspanne: Numeric rating scale at 3 and 6 months.

Presence of hypoesthesia (non-painful) at the saphenectomy site at 3 and 6 months using a numeric rating scale (NRS 0-10).

The NRS (Numeric Rating Scale) is a validated and widely used tool for assessing pain intensity in adults, particularly in postoperative and critical care settings. It allows for a simple, reproducible, and easily administered measurement, including during repeated assessments at the patient's bedside.

The NRS scale consists of asking the patient to rate their pain on a numeric scale from 0 to 10, where:

0 corresponds to no pain at all 10 corresponds to the worst pain imaginable

Numeric rating scale at 3 and 6 months.
Neuropathic characterization
Tijdsspanne: At 48 hours, 3 months, and 6 months.

Quantification of the modified DN4 score at the harvest site at 48 hours, 3 months, and 6 months.

Modified DN4 ≥ 3/8: high probability of neuropathic pain Modified DN4 < 3/8: neuropathic pain unlikely

At 48 hours, 3 months, and 6 months.
Block safety
Tijdsspanne: Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Number of adverse events related to the adductor canal block observed during the hospital stay, including hematoma, infection, nerve injury, cardiovascular complications, motor block, and signs of local anesthetic systemic toxicity.
Assessed daily during hospitalization until patient is discharge from the hospital (an average of 7 days), up to 60 days.
Opioid-related side effects
Tijdsspanne: Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Incidence of common opioid-related side effects in each group, including nausea, vomiting, and constipation.
Each time the patient takes opioids during in the postoperative period until discharge from the hospital (an average of 7 days), up to 60 days.
Time to extubation
Tijdsspanne: At extubation
Time to extubation after adductor canal block
At extubation

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Use of co-analgesia
Tijdsspanne: Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Number of treatments used and frequency of use (lidocaine-ketamine cream, NSAIDs, gabapentinoids, etc.)
Assessed once daily total co-analgesic doses administered, until discharge (an average of 7 days), up to 60 days.
Postoperative quality of life
Tijdsspanne: At 3 and 6 months postoperatively

EQ-5D score quantification measured at 3 and 6 months postoperatively. The EQ-5D (EuroQol - 5 Dimensions) is a standardized and validated instrument used to assess health-related quality of life across two components. It is widely used in clinical research to measure the overall impact of a medical intervention on patients' functional status and well-being.

It explores five dimensions of health:

  • Mobility
  • Self-care
  • Usual activities
  • Pain / discomfort
  • Anxiety / depression

Each dimension is assessed across 5 levels of severity:

  • No problems
  • Slight problems
  • Moderate problems
  • Severe problems
  • Extreme problems / inability

The combination of responses generates a 5-digit health profile, which can be converted into an EQ-5D index.

1.0: Represents perfect health. 0.0: Represents a state considered equivalent to death. Negative values: Health states deemed "worse than death."

At 3 and 6 months postoperatively
Opioid use
Tijdsspanne: At 3 and 6 months postoperatively
Opioid use at 3 and 6 months postoperatively, assessed by the presence or absence of opioid use and the type of opioid used.
At 3 and 6 months postoperatively

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 augustus 2026

Primaire voltooiing (Geschat)

31 december 2027

Studie voltooiing (Geschat)

31 december 2027

Studieregistratiedata

Eerst ingediend

2 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

23 juli 2026

Eerst geplaatst (Werkelijk)

29 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

23 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data (IPD) will not be shared, as study documents are available only in French. However, upon reasonable request, the investigators will provide the study protocol, informed consent form, statistical analysis plan, and any other relevant documents.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren